PIK3CA and cervical cancer: Together with the previously published findings, the current observations further suggest that molecular inhibitors targeting the PI3K/Akt pathway may improve the outcome by cisplatin-based CCRT in locally advanced cervical cancers harboring PIK3CA mutation.